SAVA Cassava Sciences Inc

USD 21.73 0.99 4.773385
Icon

Cassava Sciences Inc (SAVA) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 21.73

+0.99 (+4.77)%

USD 0.92B

0.91M

USD 75.00(+245.14%)

USD 103.33 (+375.52%)

Icon

SAVA

Cassava Sciences Inc (USD)
COMMON STOCK | NSD
USD 21.73
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.92B

USD 103.33 (+375.52%)

USD 21.73

Cassava Sciences Inc (SAVA) Stock Forecast

USD 75.00
(+245.14%)

Based on the Cassava Sciences Inc stock forecast from 1 analysts, the average analyst target price for Cassava Sciences Inc is USD 75.00 over the next 12 months. Cassava Sciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cassava Sciences Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Cassava Sciences Inc’s stock price was USD 21.73. Cassava Sciences Inc’s stock price has changed by +2.55% over the past week, +10.30% over the past month and -0.78% over the last year.

No recent analyst target price found for Cassava Sciences Inc
No recent average analyst rating found for Cassava Sciences Inc

Company Overview Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate i...Read More

6801 N. Capital of Texas Highway, Austin, TX, United States, 78731

29

December

USD

USA

Adjusted Closing Price for Cassava Sciences Inc (SAVA)

Loading...

Unadjusted Closing Price for Cassava Sciences Inc (SAVA)

Loading...

Share Trading Volume for Cassava Sciences Inc Shares

Loading...

Compare Performance of Cassava Sciences Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for SAVA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Cassava Sciences Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -3.06 (-0.76%) USD107.38B 29.93 21.06

ETFs Containing SAVA

Symbol Name SAVA's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Cassava Sciences Inc (SAVA) Stock

Based on ratings from 1 analysts Cassava Sciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on SAVA's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for SAVA is USD 75.00 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 75.

Unfortunately we do not have enough data on SAVA's stock to indicate if its overvalued.

The last closing price of SAVA's stock was USD 21.73.

The most recent market capitalization for SAVA is USD 0.92B.

Based on targets from 1 analysts, the average taret price for SAVA is projected at USD 75.00 over the next 12 months. This means that SAVA's stock price may go up by +245.14% over the next 12 months.

We can't find any ETFs which contains Cassava Sciences Inc's stock.

As per our most recent records Cassava Sciences Inc has 29 Employees.

Cassava Sciences Inc's registered address is 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731. You can get more information about it from Cassava Sciences Inc's website at https://www.cassavasciences.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...